Discussion Guide — Chapter 8

1. "Someone says Ozempic makes you lose 15% of your body weight. What do you ask?"

Open here, before any content. Listen for: "in whom?" and "over how long?" and — from students who absorbed Chapter 5 — "which analysis?" If nobody asks about population, that is your lesson plan for the next twenty minutes.

2. "Convert SELECT's 20% into something a patient could act on."

Do it on the board with them. Listen for: the moment the absolute figure lands. Then ask: which number would you lead with, if you were the manufacturer? If you were a critic? If you were the patient's doctor? The answer differs for each, and none of them is lying.

3. "The black box warning. Say the accurate version."

Have several students attempt it aloud. Listen for: the ones who go alarmist and the ones who go dismissive; both will appear. The accurate version requires four elements — rodent finding, species difference, no human signal, real contraindication in MEN2 — and most first attempts drop one. The one most often dropped is the last, which is the one that matters to an actual patient.

4. "The weight comes back. Does the drug work?"

Listen for: the override-versus-replace explanation, then for someone reaching the antihypertensive comparison. Then push into the uncomfortable part: why do we expect permanence from a weight drug and not from a blood pressure drug? The answer is about the moral framing of weight, and it is worth naming explicitly. This discussion frequently becomes personal; let it, and be careful.

5. "SELECT proves it works and nobody knows why. Is that a problem?"

Listen for: students separating efficacy from mechanism. Then the practical consequence: what can you extrapolate if you don't know the mechanism? (Very little — which is the reason the chapter declines to rate primary prevention.) Students who get this read Chapter 10 far better.

6. "The chapter declines to rate cardiovascular benefit in primary prevention. Is that caution or evasion?"

The best closing question. Listen for: the arithmetic — absolute benefit scales with baseline risk, harms do not. A student who can state that has understood both this chapter and Chapter 5 §5.8. Then ask what it would take to earn the rating, and let them discover that the trial would have to be much larger and longer than SELECT, which is why it has not been run.